{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:17:26Z","timestamp":1760235446273,"version":"build-2065373602"},"reference-count":50,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>In this study, we aimed to assess the prevalence of uncommon staining patterns found during testing for the presence of antinuclear antibodies (ANA) and to determine their association with certain antibodies and clinical diagnoses. Presence of ANA and the staining pattern was determined in 10955 samples using indirect immunofluorescence (IIF) on HEp-2 cells. ANA-positive samples were assessed for presence of 14 specific antibody types using a microbead based system. Demographic data (age, sex) and clinical diagnoses were collected from the referral documentation. Particular staining patterns were then compared with a representative comparison group comprised of samples with common staining patterns using these criteria. There were 22 patterns present in less than 3% of samples each and these were jointly present in 42.43% of ANA-positive samples. Specific antibodies were found in proportions similar to the comparison group (46.06%) and varied significantly between patterns. Likewise, there were significant differences in antibody distribution in particular patterns. Some patterns were associated with presence of rheumatic diseases or inflammatory arthropathies, while in others there was a concurrent diagnosis of liver disease, or a neoplastic process. Many of the uncommon IIF patterns have distinctive characteristics that warrant further investigation in order to determine their role in diagnosing various diseases, not limited only to the illnesses of the rheumatic spectrum. IIF on HEp-2 cells remains an irreplaceable method because of the diversity of ANA, only a number of which can be detected using other standardised methods.<\/jats:p>","DOI":"10.3390\/jcm10173866","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T11:01:37Z","timestamp":1630321297000},"page":"3866","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Properties of Uncommon Indirect Immunofluorescence Staining Patterns Determined during Antinuclear Antibody Detection on HEp-2 Cells"],"prefix":"10.3390","volume":"10","author":[{"given":"Nada","family":"Tomi\u0107 Sremec","sequence":"first","affiliation":[{"name":"Department of Laboratory Diagnostics, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Kozmar","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josip","family":"Sremec","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Sveti Duh, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branimir","family":"Ani\u0107","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, \u0160alata 3, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drago","family":"Batini\u0107","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, \u0160alata 3, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/ard.2009.127100","article-title":"ANA screening: An old test with new recommendations","volume":"69","author":"Meroni","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/labmed\/lmy024","article-title":"Antinuclear Antibodies: Marker of Diagnosis and Evolution in Autoimmune Diseases","volume":"49","author":"Sur","year":"2018","journal-title":"Lab. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e000793","DOI":"10.1136\/rmdopen-2018-000793","article-title":"Systemic lupus erythematosus: State of the art on clinical practice guidelines","volume":"4","author":"Tamirou","year":"2018","journal-title":"RMD Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/art.10558","article-title":"Guidelines for immunologic laboratory testing in the rheumatic diseases: Anti-DNA antibody tests","volume":"47","author":"Kavanaugh","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102400","DOI":"10.1016\/j.autrev.2019.102400","article-title":"ANA as an entry criterion for the classification of SLE","volume":"18","author":"Pisetsky","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren\u2019s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","first-page":"686","article-title":"Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sj\u00f6gren\u2019s syndrome","volume":"30","author":"Retamozo","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000024418","article-title":"Antinuclear antibody- and extractable nuclear antigen-related diseases","volume":"123","author":"Hiepe","year":"2000","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/rheumatology\/39.6.581","article-title":"Antinuclear antibodies: Cause of disease or caused by disease?","volume":"39","author":"Smeenk","year":"2000","journal-title":"Rheumatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.autrev.2018.03.002","article-title":"Solid phase assays versus automated indirect immunofluorescence for detection of antinuclear antibodies","volume":"17","author":"Claessens","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1515\/cclm-2017-0905","article-title":"Screening for connective tissue disease-associated antibodies by automated immunoassay","volume":"56","author":"Willems","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.autrev.2012.02.013","article-title":"Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis","volume":"12","author":"Vermeersch","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2013-203863","article-title":"International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies","volume":"73","author":"Damoiseaux","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrrheum.2017.74","article-title":"Antinuclear antibody testing\u2014Misunderstood or misbegotten?","volume":"13","author":"Pisetsky","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Meroni, P.L., Bizzaro, N., Cavazzana, I., Borghi, M.O., and Tincani, A. (2014). Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: Strengths and limitations. BMC Med., 12.","DOI":"10.1186\/1741-7015-12-38"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/ard.2003.016303","article-title":"Anti-dsDNA antibodies and disease classification in antinuclear antibody positive patients: The role of analytical diversity","volume":"63","author":"Haugbro","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.autrev.2011.06.005","article-title":"Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay","volume":"10","author":"Vermeersch","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13075-017-1380-3","article-title":"Emerging technologies in autoantibody testing for rheumatic diseases","volume":"19","author":"Olsen","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3389\/fimmu.2015.00412","article-title":"Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014\u20132015","volume":"6","author":"Chan","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1177\/0961203316640920","article-title":"Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015","volume":"25","author":"Chan","year":"2016","journal-title":"Lupus"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.autrev.2017.10.006","article-title":"The inter-observer reading variability in anti-nuclear antibodies indirect (ANA) immunofluorescence test: A multicenter evaluation and a review of the literature","volume":"16","author":"Rigon","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1191\/0961203305lu2069oa","article-title":"Impact of external quality assessment on antinuclear antibody detection performance","volume":"14","author":"Pham","year":"2005","journal-title":"Lupus"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.3748\/wjg.v22.i6.1966","article-title":"Anti-rods\/rings autoantibody generation in hepatitis C patients during interferon-\u03b1\/ribavirin therapy","volume":"22","author":"Keppeke","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/1744666X.2019.1562903","article-title":"Anti-DFS70 antibodies: An update on our current understanding and their clinical usefulness","volume":"15","author":"Mahler","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_27","unstructured":"World Health Organization (2021, May 14). ICD-10 Version 2010. Available online: https:\/\/icd.who.int\/browse10\/2010\/en."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0889-8561(02)00074-7","article-title":"Origin of late-onset autoimmune disease","volume":"23","author":"Hsu","year":"2003","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clim.2018.04.002","article-title":"Immune senescence, epigenetics and autoimmunity","volume":"196","author":"Ray","year":"2018","journal-title":"Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.3899\/jrheum.120598","article-title":"Anti-DFS70\/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases","volume":"39","author":"Mahler","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/art.20836","article-title":"Guidelines for immunologic laboratory testing in the rheumatic diseases: Anti-Sm and anti-RNP antibody tests","volume":"51","author":"Schur","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1136\/ard.2008.104190","article-title":"Antinuclear antibodies directed against proliferating cell nuclear antigen are not specifically associated with systemic lupus erythematosus","volume":"68","author":"Vermeersch","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/art.1780330307","article-title":"Dissociation of immune responses to the ss-a (ro) 52-kd and 60-kd polypeptides in systemic lupus erythematosus and Sj\u00f6gren\u2019s syndrome","volume":"33","author":"Fox","year":"1990","journal-title":"Arthritis Rheum."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.autrev.2012.02.012","article-title":"The clinical significance of autoantibodies to the proliferating cell nuclear antigen (PCNA)","volume":"11","author":"Mahler","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: New and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.162.2.459","article-title":"Lupus autoantibodies target ribosomal P proteins","volume":"162","author":"Elkon","year":"1985","journal-title":"J. Exp. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/jcla.20248","article-title":"Anti-histones antibodies in systemic lupus erythematosus: Prevalence and frequency in neuropsychiatric lupus","volume":"2","author":"Sun","year":"2008","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1515\/cclm-2018-0188","article-title":"International consensus on antinuclear antibody patterns: Definition of the AC-29 pattern associated with antibodies to DNA topoisomerase I","volume":"56","author":"Andrade","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: An American College of rheumatology\/European League against rheumatism collaborative initiative","volume":"72","author":"Khanna","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/art.20096","article-title":"Anti-DFS70 antibodies in 597 healthy hospital workers","volume":"50","author":"Watanabe","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/1744666X.2019.1596801","article-title":"The long-awaited \u2018pseudo-DFS pattern\u2019","volume":"15","author":"Infantino","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clim.2007.07.016","article-title":"Clinical and serological features of patients with autoantibodies to GW\/P bodies","volume":"125","author":"Bhanji","year":"2007","journal-title":"Clin. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0896-8411(03)00033-7","article-title":"Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: A multicenter study","volume":"20","author":"Miyachi","year":"2003","journal-title":"J. Autoimmun."},{"key":"ref_44","unstructured":"Conrad, K., Sch\u00f6ssler, W., Hiepe, F., and Fritzler, M.J. (2017). Autoantigens Autoantibodies Autoimmunity, Pabst Science. [2nd ed.]."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.0300-9475.2004.01353.x","article-title":"Clinical association of anti-golgi autoantibodies and their autoantigens","volume":"59","author":"Hong","year":"2004","journal-title":"Scand. J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/clin.1995.1013","article-title":"Integral membrane proteins associated with the nuclear lamina are novel autoimmune antigens of the nuclear envelope","volume":"74","author":"Konstantinov","year":"1995","journal-title":"Clin. Immunol. Immunopathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1046\/j.1365-2249.2001.01568.x","article-title":"Anti-cytokeratin antibodies in sera of the patients with autoimmune hepatitis","volume":"125","author":"Murota","year":"2001","journal-title":"Clin. Exp. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Hu, S.L., Zhao, F.R., Hu, Q., and Chen, W.X. (2014). Meta-analysis assessment of gp210 and Sp100 for the diagnosis of primary biliary cirrhosis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101916"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fimmu.2015.00041","article-title":"Anti-rods\/rings: A human model of drug-induced autoantibody generation","volume":"6","author":"Calise","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaut.2006.09.001","article-title":"Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus","volume":"27","author":"Wandstrat","year":"2006","journal-title":"J. Autoimmun."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/17\/3866\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:54:12Z","timestamp":1760165652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/17\/3866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,28]]},"references-count":50,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["jcm10173866"],"URL":"https:\/\/doi.org\/10.3390\/jcm10173866","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2021,8,28]]}}}